


Registration No: 01249401

ONYX CLINICAL LIMITED
REPORT AND UNAUDITED FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020



ONYX CLINICAL LIMITED

Report of the Directors for the year ended 31 December 2020


The Directors present their report and the unaudited financial statements for the year ended 31 December 2020. The Company was dormant and did not trade during the year.

The Directors who held office during the year and the period to date were:

D Gerrard
C Gough

No Director has, or has had, a material interest in the Company, directly or indirectly at any time during the year.

The report of the Directors was approved by the Board and signed on its behalf by:



D Gerrard
Director

Date: 30 April 2021

Balance sheet at 31 December 2020


	Note	2020 £000	2019 £000
Current assets			
Debtors: amounts falling due within one year			
Amounts owed by Group fellow subsidiaries		2,411	2,411
Creditors: amounts falling due within one year			
Amounts owed to Group fellow subsidiaries		(11,014)	(11,014)
Net liabilities		<u>(8,603)</u>	<u>(8,603)</u>
Capital and reserves			
Called up share capital	3	1	1
Profit and loss account		(8,604)	(8,604)
Equity shareholder's deficit		<u>(8,603)</u>	<u>(8,603)</u>

For the year ended 31 December 2020, the Company was entitled to exemption from audit under Section 480 of the Companies Act 2006 relating to dormant companies.

Directors' Responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with Section 476; and
- The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements were approved by the Board and signed on its behalf by:


D Gerrard
Director

Date: 30 April 2021

Notes to the financial statements as at 31 December 2020

1. PRINCIPAL ACCOUNTING POLICIES

The financial statements are prepared on the going concern basis in accordance with applicable accounting standards, under the historical cost convention, and in accordance with the Companies Act 2006. FRS 102 provides relief to dormant companies from restating their transition date Balance Sheets until there is any change in their existing balances or the company undertakes any new transactions.

Transactions with other companies within the Veolia Group are not disclosed as the Company has taken advantage of the exemption under FRS 102 section 33.1 A.

2. ACTIVITY AND DIRECTORS

During the financial year and the preceding financial year the Company did not trade. Consequently a Statement of Comprehensive Income has not been disclosed.

The Directors received no emoluments for their services to the Company (2019: £nil).

The Company had no employees during the year (2019: nil).

3. SHARE CAPITAL

	2020 £000	2019 £000
Allotted, called up and fully paid		
1,000 ordinary shares of £1 each	1	1
	<u>1</u>	<u>1</u>

4. IMMEDIATE PARENT AND ULTIMATE CONTROLLING PARTY

The immediate parent company is Veolia Environmental Services (UK) Plc, a company incorporated in the UK.

Veolia Environmental Services (UK) Plc is an intermediate parent undertaking that prepares consolidated financial statements, including Onyx Clinical Limited, which are publicly available. Copies of the consolidated financial statements for Veolia Environmental Services (UK) Plc are available from the registered office at 210 Pentonville Road, London, N1 9JY.

The ultimate parent and controlling company is Veolia Environnement S.A., a company incorporated in France. Consolidated financial statements are prepared by Veolia Environnement S.A. Copies of the consolidated financial statements for Veolia Environnement S.A. are available from the registered office at 21 rue La Boétie, 75008 Paris, France.